Product Information
LOTEPREDNOL 0.5% OPHTHALMC GEL is a generic product labeled by Bausch & Lomb Incorporated, priced at $18.1880 per GM under NDC 24208050801. Its NADAC has been published 281 times since May 19, 2021.
FDA first approved this application on Sep 28, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the loteprednol etabonate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
5 mg/g
Manufacturer
Bausch & Lomb IncorporatedNDC
24208050801
Classification
Generic
Dosage Form
GEL
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
LOTEPREDNOL ETABONATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA202872FDA Approved
9/28/2012
TE Code
AB
On Market Since
2/17/2021
Pharmacological Classes
Price Statistics
The NADAC for LOTEPREDNOL 0.5% OPHTHALMC GEL has been published 281 times since May 19, 2021, and over the history we have for it it has declined 37.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $18.1880 per GM |
|---|---|
| All-time high | $35.5296 (May 11, 2022) |
| All-time low | $14.0549 (Jun 18, 2025) |
| 52-week high | $18.1880 |
| 52-week low | $14.2657 |
| Median price | $26.8674 |
| Average price | $23.7383 |
| Largest weekly change | -37.4% (Nov 20, 2024) |
| Weeks tracked | 281 |
| Tracking since | May 19, 2021 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
loteprednol etabonate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LOTEPREDNOL 0.5% OPHTHALMC GEL?
The current National Average Drug Acquisition Cost (NADAC) for LOTEPREDNOL 0.5% OPHTHALMC GEL, manufactured by Bausch & Lomb Incorporated, is $18.1880 per GM (NDC 24208050801), effective Sep 30, 2026.
How has the price of LOTEPREDNOL 0.5% OPHTHALMC GEL changed over time?
Over the history we have for it, the NADAC for LOTEPREDNOL 0.5% OPHTHALMC GEL has declined 37.0%. It has been tracked across 281 weekly CMS publications since May 19, 2021.
What are the highest and lowest recorded NADAC prices for LOTEPREDNOL 0.5% OPHTHALMC GEL?
Since May 19, 2021, the NADAC for LOTEPREDNOL 0.5% OPHTHALMC GEL has ranged from a low of $14.0549 (Jun 18, 2025) to a high of $35.5296 (May 11, 2022), with a median of $26.8674 per GM.
Are there cheaper alternatives to LOTEPREDNOL 0.5% OPHTHALMC GEL?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LOTEPREDNOL 0.5% OPHTHALMC GEL in a comparable dosage form, but none are currently priced below it.
Who manufactures LOTEPREDNOL 0.5% OPHTHALMC GEL?
LOTEPREDNOL 0.5% OPHTHALMC GEL (NDC 24208050801) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a generic product.